{"nctId":"NCT03097484","briefTitle":"The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels","startDateStruct":{"date":"2015-07-25","type":"ACTUAL"},"conditions":["Neonatal Abstinence Syndrome","Aromatherapy"],"count":38,"armGroups":[{"label":"Standard therapy plus Aromatherapy","type":"EXPERIMENTAL","interventionNames":["Drug: lavender and chamomile essential oils"]},{"label":"Standard therapy ALONE","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"lavender and chamomile essential oils","otherNames":["Lavendula, chamomilla"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infants greater than or equal to 36 weeks EGA\n* Intrauterine opioid exposure\n* Primary diagnosis of NAS\n* Parental permission to participate\n\nExclusion Criteria:\n\n* Infants less than 36 weeks EGA\n* Major congenital anomalies\n* Latrogenic drug withdrawal\n* Diagnosis of infection or respiratory distress\n* Prior initiation of opioid replacement therapy\n* Non-English speaking\n* Infants with respiratory conditions","healthyVolunteers":false,"sex":"ALL","maximumAge":"2 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Length of Hospitalization","description":"How long the infant remains hospitalized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"10.1"},{"groupId":"OG001","value":"11.4","spread":"6.6"}]}]}]},{"type":"SECONDARY","title":"Length of Medication Therapy","description":"How long the infant requires medication to treat symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":"10.1"},{"groupId":"OG001","value":"7.4","spread":"6.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":[]}}}